Sodium phenylbutyrate is an nitrogen-binding drug used as a medication for urea cycle disorders and as adjuvant therapy for various conditions. It helps remove excess ammonia from blood by changing it into substances that can be removed from the body in urine. Sodium phenylbutyrate is used to treat the biochemical abnormality that causes some types of urea cycle disorders, which are inherited metabolic disorders that prevent the liver from removing ammonia from the blood. The drug is prescribed along with dietary protein restriction and supplemental essential amino acids. It is available in oral powder, oral tablet, and intravenous forms for clinical management of acute hyperammonemia and chronic management of deficiencies of the urea cycle enzymes carbamoyl phosphate synthetase I, ornithine transcarbamoylase or argininosuccinic acid synthetase.
The global Sodium Phenylbutyrate Market is estimated to be valued at US$ 1.92 Billion in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The Sodium Phenylbutyrate Market is Expected to be Flourished by Increasing Prevalence of Urea Cycle Disorders (as mentioned in the heading). Urea cycle disorders are a group of rare inborn errors of metabolism that affect the body’s ability to remove ammonia from the blood. According to the Urea Cycle Disorders Consortium, the estimated prevalence of UCD is 1 in 35,000 live births worldwide. The increasing incidence of urea cycle disorders is expected to propel the demand for sodium phenylbutyrate for its management over the forecast period.
Additionally, rising awareness about the available diagnostic and treatment options for inherited metabolic diseases including UCDs is also expected to boost the market growth. Various initiatives are being taken by government and non-profit organizations to spread awareness about rare diseases. This is augmenting early diagnosis and treatment of such conditions, thereby supporting the sodium phenylbutyrate market expansion.
The global sodium phenylbutyrate market can be segmented based on type, application, end-use industry, and region. Based on type, the sodium phenylbutyrate granular segment currently dominates the market accounting for over 60% share as it is easily administrable and does not require refrigeration. The sodium phenylbutyrate liquid segment is expected to witness fastest growth over the forecast period due to rise in preference for liquid medicines.
Political: The sodium phenylbutyrate market is regulated by various rules and regulations set by authorities like FDA regarding drug manufacturing and approval. Stringent regulations can hamper market growth.
Economic: Fluctuations in raw material prices impacts the production cost of sodium phenylbutyrate. Rise in per capita healthcare spending in developing nations is driving market growth.
Social: Improving patient access to rare disease treatment drives market growth. Growing preference for personalized medicine also presents growth opportunities.
Technological: Advances in drug delivery methods is supporting development of alternative formulations like suspensions, granules, and liquids. Researchers are working on developing more effective derivatives.
The Global Sodium Phenylbutyrate Market Demand is expected to witness high growth at a CAGR of 4.2% during the forecast period of 2023 to 2030 to reach a market size of US$ 2.7 Bn by 2030.
Regional analysis: North America currently dominates the market accounting for over 40% share due to presence of major manufacturers and favorable reimbursement policies. Asia Pacific is expected to witness fastest growth over the forecast period with countries like China and India emerging as lucrative markets.
Key players: Key players operating in the sodium phenylbutyrate market are Procter & Gamble (P&G) Chemicals, CREMER, Wilmar, VVF Ltd., KLK OLEO, Inoue Perfumery MFG, Wuhan Yuancheng Gongchuang, Changsha Jianglong Chemicals, Godrej Industries. Procter & Gamble (P&G) Chemicals dominates the market with over 20% share owing to its robust brand presence and wide product portfolio.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it